Pharmacogenomic strategies in drug safety

Drug safety is a priority for drug developers and regulatory agencies. Pharmacogenomics is a powerful tool that can be used to manage clinical risks as well as resolve the mechanistic basis of adverse drug events. Advances in the science of drug safety, increased commitment to pharmacogenomics by drug companies, and enhanced regulatory review infrastructure at the U.S. FDA have helped to advance the application of safety pharmacogenomics in drug development and public health decision-making. This review highlights some successes in discovery and translation of pharmacogenomic biomarkers for adverse drug events and outlines future strategies to optimize the development and clinical application of pharmacogenomic information.